Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghel, Nazanin, Delgado, Diego Hernan, Lipton, Jeffrey Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552150/
https://www.ncbi.nlm.nih.gov/pubmed/28831263
http://dx.doi.org/10.2147/VHRM.S108874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552150/
https://www.ncbi.nlm.nih.gov/pubmed/28831263
http://dx.doi.org/10.2147/VHRM.S108874

Ejemplares similares